GLP-1 therapy may also slow digestion
Most people who have taken GLP-1 drugs say they got them from one of their doctors (76%), while about one in six (17%) say they got them from an online provider or website, and one in ten (9%) report getting them from a medical spa or aesthetic medical center
There are several Phase 3 trials evaluating GLP-1s for conditions, such as prediabetes, Alzheimer's disease, diabetic retinopathy and osteoarthritis of the knee (in patients with obesity)
These could be especially helpful during the menopausal transition, when the diagnosis of these conditions increases
Pharmacoepidemiol Drug Saf 2012;21(Suppl 1):1217 [DOI] [PubMed] [Google Scholar] 31.Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS
In an exploratory analysis of the results of the REWIND trial, a CVOT for dulaglutide (another once-weekly GLP-1RA), a highly significant reduction of 13%-14% was observed in the risk of substantive cognitive impairment, also after adjustment for baseline scores, age ,sex, ethnic origin or education [26]
